Study details regulation of vital tumor suppressor gene p53September 06, 2007Related modifications at single DNA site seen to have contradictory effects (PHILADELPHIA) - So vital is the p53 tumor suppressor gene in controlling cancer that its dysfunction is linked to more than half of human cancers. At the same time, the gene's capacity for shutting down cell growth, even causing cells to commit suicide if necessary, is so absolute that it must be tightly regulated to maintain the optimal balance between protecting against cancer and permitting normal growth. Now, a study by scientists at The Wistar Institute reveals new levels of subtlety in the body's management of this all-important tumor suppressor gene and the protein it produces. The experiments show that, while the addition of a specific molecule at a particular site on the p53 protein prevents it from acting, the addition of a second copy of the same molecule at the same site reverses the effect, sending p53 into action. Further, removal of the second copy returns the protein to its repressed state.
In addition to the implications for understanding the activity of the p53 gene, the findings also outline an important new cycle of gene-regulating modifications involving the addition and removal of the molecules, called methyl groups, that may be widespread in the genome. A report on the study appears in the September 6 issue of Nature. "The p53 tumor suppressor is extremely potent in halting cell growth," says Shelley L. Berger, Ph.D., the Hilary Koprowski Professor at The Wistar Institute and senior author on the study. "So, as critical as p53 is in protecting against the unchecked growth of cancer, you don't want it constantly on. If it were always on, your cells wouldn't be able to grow normally. Yet it needs to be constantly on call for activation against cancer and other aberrant cellular developments. Our study shows one way that the cell, working at one particular location on the p53 protein, maintains a nuanced but firm control over the gene's activity." Responsible for tumor suppression throughout the body, the p53 gene is mutated or otherwise disabled in a majority of human cancers. When working properly, the protein produced by the p53 gene acts by binding to DNA to activate other genes that direct cells with damaged DNA to cease dividing until the damage can be repaired. Cells with such damage include cancer cells, since all cancers track to genetic flaws of one kind or another, whether inherited or acquired. If repairs cannot be made, p53 commands the cells with damaged DNA to self-destruct so they are no longer a danger to the body. This powerful ability of p53 to shut down cell division and induce cell death points to why fine-tuned regulatory mechanisms such as the one outlined in the new study are crucial for cellular survival. In a previous study published in Nature in November 2006, Berger and her colleagues showed that the addition of a single methyl group - a tiny molecule consisting of one carbon and three hydrogen atoms - at a specific site on the p53 protein was sufficient to repress its activity. In the current study, the researchers found that the addition of a second methyl group at the same site reversed the effect. With the pair of methyl groups in place, the site is able to attract and bind a molecule called 53bp1, itself required for the p53 protein to bind to DNA to launch the genes responsible for carrying out its tumor-suppressing mission. With one methyl group in place, the site is said to be monomethylated; with two in place, it is dimethylated. "An important finding from our study is that the dimethylation mark is the required recognition site for 53bp1 on the p53 protein," says Jing Huang, Ph.D., lead author on the Nature study. "If you remove that mark, 53bp1 cannot associate with the p53 protein, and p53's activity will be reduced." The Wistar Institute | |||||||||||||||||||||
|
Related Suppressor Gene Current Events and Suppressor Gene News Articles Science teams at Cold Spring Harbor Laboratory identify 13 new tumor-suppressor genes in liver cancer Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise. At Cold Spring Harbor Laboratory (CSHL), five different research groups have now combined their expertise to speed up the rate of discovering cancer-related genes and validating their function in living animals. New journal shows half-broken gene is enough to cause cancer Tumour suppressor genes do not necessarily require both alleles to be knocked out before disease phenotypes are expressed. Research published in BioMed Central's new open access journal PathoGenetics reveals that only one allele of SMAD4 has to be damaged to put a person at risk of pancreatic and colorectal cancer. UC Davis researchers discover a key to aggressive breast cancer In trying to find out why HER2-positive breast cancer can be more aggressive than other forms of the disease, UC Davis Cancer Center researchers have surprisingly discovered that HER2 itself is the culprit. By shutting down its own regulator gene, HER2 creates a permissive environment for tumor growth. Novel genetic screens provide panoramic views of cellular systems Despite the rise of systems biology, many geneticists continue to probe genes in isolation. They even use cutting-edge RNA interference (RNAi) technology to knock down one gene at a time. This approach often yields a narrow view of cellular systems. '1-hit' event provides new opportunity for colon cancer prevention, say Fox Chase researchers More than 30 years ago, Alfred Knudson Jr., M.D., Ph.D., revolutionized the field of cancer genetics by showing that a person must lose both their paternal and maternal copies of a particular class of cancer-inhibiting genes, called tumor-suppressor genes, in order to develop cancer. Early stage colon cancer characterized by inactivation of gatekeeper gene The absence or inactivation of the RUNX3 gatekeeper gene paves the way for the growth and development of colon cancer, Singapore scientists report in the Sept. issue of the journal Cancer Cell. Previous studies have shown that RUNX3 plays a role in gastric, breast, lung and bladder cancers. International team reveals first prognosticator of survival in aggressive cancer The tumor suppressor gene pRb2/p130 may provide the first independent prognostic biomarker in cases of soft tissue sarcoma (STS). New insights into the regulation of PTEN tumor suppression function The PTEN tumor suppressor gene controls numerous biological processes including cell proliferation, cell growth and death. But PTEN is frequently lost or mutated; in fact, alteration of the gene is so common among various types of human cancer that PTEN has become one of the most frequently mutated of all tumor suppressors. A new cellular pathway linked to cancer is identified by NYU researchers In the life of a cell, the response to DNA damage determines whether the cell is fated to pause and repair itself, commit suicide, or grow uncontrollably, a route leading to cancer. Gene therapy increases survival for end-stage head and neck cancer A gene therapy invented at The University of Texas M. D. Anderson Cancer Center is the first to succeed in a U.S. phase III clinical trial for cancer, as announced today at the American Society of Gene Therapy annual meeting in Boston. More Suppressor Gene Current Events and Suppressor Gene News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||